Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 2Unknown 1

Sponsor Class

INDUSTRY 11OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 548pembrolizumab 385Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Has results × pemigatinib × Clear all
NCT04294277 2025-04-18

PEGASUS

European Association of Urology Research Foundation

Phase 2 Terminated
2 enrolled 6 charts
Genitourinary

Carcinoma, Transitional Cell

NCT04088188 2024-05-06

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Academic and Community Cancer Research United

Phase 1 Terminated
8 enrolled 14 charts
Gastrointestinal

Cholangiocarcinoma

NCT04096417 2024-02-21

Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations

Academic and Community Cancer Research United

Phase 2 Unknown
14 enrolled 11 charts
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡